Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials

PURPOSE: For patients with hemophilia B, extended half-life factor IX (FIX) products are available for prophylaxis and for treating bleeds. Different methods are used to extend the half-lives of recombinant FIX Fc fusion protein (rFIXFc) and nonacog beta pegol (N9-GP). This affects their biodistribu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mancuso, Maria Elisa, Eriksson, Daniel, Falk, Aletta, Hakimi, Zalmai, Wojciechowski, Piotr, Wdowiak, Marlena, Klamroth, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390690/
https://www.ncbi.nlm.nih.gov/pubmed/37534261
http://dx.doi.org/10.2147/JBM.S389094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390690/
https://www.ncbi.nlm.nih.gov/pubmed/37534261
http://dx.doi.org/10.2147/JBM.S389094

Ejemplares similares